Fiche centre
Chungbuk National University Hospital
Cheongju-si — South Korea
Essais liés13clinical trials
VilleCheongju-silocalisation
PaysSouth Korealocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT04606381
Essais cliniques associés
13| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| INBRX-106 - Hexavalent OX40 agonist antibody | Cancer | Phase 1/2 | NCT04198766 | Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | RECRUITING |
| Survodutide | Maladie rénale chronique | Phase 3 | NCT06077864 | A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT) | COMPLETED |
| Selatogrel | Maladie coronarienne | Phase 3 | NCT04957719 | SOS-AMI — Selatogrel Outcome Study in Suspected Acute Myocardial Infarction | ENROLLING_BY_INVITATION |
| Pumitamig | Cancer | Phase 3 | NCT07173751 | ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer | RECRUITING |
| Adagrasib | Cancer | Phase 2/3 | NCT04613596 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | RECRUITING |
| In-hospital staged complete revascularization | Maladie coronarienne | Non applicable | NCT07741721 | Optimal Timing of Staged Complete Revascularization in STEMI With Multivessel Disease (OPTION-STEMI2) | RECRUITING |
| BMS-986504 | Cancer | Phase 2/3 | NCT07063745 | MountainTAP-29 — A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion | RECRUITING |
| Nivolumab | Cancer | Phase 3 | NCT06561386 | RELATIVITY1093 — A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | RECRUITING |
| BI 690517 | Maladie rénale chronique | Phase 3 | NCT06531824 | EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | ACTIVE_NOT_RECRUITING |
| Vicadrostat | Insuffisance cardiaque | Phase 3 | NCT06424288 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | RECRUITING |
| Ami-LC-MD | Cancer | Phase 1 | NCT04606381 | PALOMA — A Study of Amivantamab Subcutaneous (SC) Administration for the Treatment of Advanced Solid Malignancies | ACTIVE_NOT_RECRUITING |
| Oxaliplatin, 5FU, leucovorin | Cancer | Phase 2 | NCT07062536 | mFOLFOX/mFOLFIRI vs. mFOLFOX in Advanced or Recurrent Biliary Tract Cancer Second-line | RECRUITING |
| Adagrasib | Cancer | Phase 3 | NCT06875310 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | RECRUITING |